RxDoctor Payments Data

David Rhodes, MD

Family Medicine · Diamond Bar, CANPI 1518968353

Payments from drug & device makers

$1,570in general payments, 2019–2025

Across 85 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$370
  • Amgen$295
  • Novo Nordisk$169
  • GSK$156
  • AstraZeneca$127
  • Pfizer$85
  • plus $369 from 11 others

What the payments were for

  • Consulting fees$201%
  • Food & beverage$1,55099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,570 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$178,165
Medicare patients
385
Services billed
2,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban220$197,363
OzempicSemaglutide137$191,126
JardianceEmpagliflozin104$131,129
MounjaroTirzepatide71$75,694
JanuviaSitagliptin Phosphate48$62,996
FarxigaDapagliflozin Propanediol53$55,603
RybelsusSemaglutide28$51,141
XareltoRivaroxaban42$51,049
TrulicityDulaglutide19$24,762
Atorvastatin Calcium1,226$15,906
MyrbetriqMirabegron13$14,141
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,200
Repatha SureclickEvolocumab12$9,989
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$9,905
Rosuvastatin Calcium448$9,801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$169$242,267165 claims
PfizerEliquis$85$197,363220 claims
Lilly USA, LLCMounjaro, Trulicity$370$100,45690 claims
MerckJanuvia$41$62,99648 claims
AstraZenecaFarxiga, Symbicort$127$59,61665 claims
GSKTrelegy Ellipta$156$11,20011 claims
AbbVieSynthroid$64$8,05393 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Diamond Bar

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →